ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer

M. Ladekarl; S. Shim; T. J. Ettrich; A. Kestler; P. Pfeiffer; L. S. Tarpgaard; A. Reinacher-Schick; A-L. Kraeft; J. Stenvang; A. Zurlo; N. Lindland Roest

doi:10.1016/j.annonc.2023.09.2590

ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer

M. Ladekarl, S. Shim, T. J. Ettrich, A. Kestler, P. Pfeiffer, L. S. Tarpgaard, A. Reinacher-Schick, A-L. Kraeft, J. Stenvang, A. Zurlo, N. Lindland Roest

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	1641P
Journal	Annals of Oncology
Volume	34
Issue number	Suppl. 2
Pages (from-to)	S907
Number of pages	1
ISSN	0923-7534
DOIs	https://doi.org/10.1016/j.annonc.2023.09.2590
Publication status	Published - Oct 2023
Event	ESMO Congress 2023 - Madrid, Spain Duration: 20 Oct 2023 → 24 Oct 2023 https://www.esmo.org/meeting-calendar/past-meetings/esmo-congress-2023

Conference

Conference	ESMO Congress 2023
Country/Territory	Spain
City	Madrid
Period	20/10/2023 → 24/10/2023
Internet address	https://www.esmo.org/meeting-calendar/past-meetings/esmo-congress-2023

Bibliographical note

Abstract No. 1641P

Access to Document

10.1016/j.annonc.2023.09.2590

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Ladekarl, M., Shim, S., Ettrich, T. J., Kestler, A., Pfeiffer, P., Tarpgaard, L. S., Reinacher-Schick, A., Kraeft, A.-L., Stenvang, J., Zurlo, A., & Roest, N. L. (2023). ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer. Annals of Oncology, 34(Suppl. 2), S907. Article 1641P. https://doi.org/10.1016/j.annonc.2023.09.2590

@article{45533cc19cd64452b115fc451af680f5,

title = "ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer",

author = "M. Ladekarl and S. Shim and Ettrich, {T. J.} and A. Kestler and P. Pfeiffer and Tarpgaard, {L. S.} and A. Reinacher-Schick and A-L. Kraeft and J. Stenvang and A. Zurlo and Roest, {N. Lindland}",

note = "Abstract No. 1641P; ESMO Congress 2023 ; Conference date: 20-10-2023 Through 24-10-2023",

year = "2023",

month = oct,

doi = "10.1016/j.annonc.2023.09.2590",

language = "English",

volume = "34",

pages = "S907",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "Suppl. 2",

url = "https://www.esmo.org/meeting-calendar/past-meetings/esmo-congress-2023",

}

Ladekarl, M , Shim, S, Ettrich, TJ, Kestler, A, Pfeiffer, P, Tarpgaard, LS, Reinacher-Schick, A, Kraeft, A-L, Stenvang, J, Zurlo, A & Roest, NL 2023, 'ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer', Annals of Oncology, vol. 34, no. Suppl. 2, 1641P, pp. S907. https://doi.org/10.1016/j.annonc.2023.09.2590

ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer. / Ladekarl, M.; Shim, S.; Ettrich, T. J. et al.
In: Annals of Oncology, Vol. 34, No. Suppl. 2, 1641P, 10.2023, p. S907.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer

AU - Ladekarl, M.

AU - Shim, S.

AU - Ettrich, T. J.

AU - Kestler, A.

AU - Pfeiffer, P.

AU - Tarpgaard, L. S.

AU - Reinacher-Schick, A.

AU - Kraeft, A-L.

AU - Stenvang, J.

AU - Zurlo, A.

AU - Roest, N. Lindland

N1 - Abstract No. 1641P

PY - 2023/10

Y1 - 2023/10

U2 - 10.1016/j.annonc.2023.09.2590

DO - 10.1016/j.annonc.2023.09.2590

M3 - Conference abstract in journal

SN - 0923-7534

VL - 34

SP - S907

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 2

M1 - 1641P

T2 - ESMO Congress 2023

Y2 - 20 October 2023 through 24 October 2023

ER -

Ladekarl M , Shim S, Ettrich TJ, Kestler A, Pfeiffer P, Tarpgaard LS et al. ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer. Annals of Oncology. 2023 Oct;34(Suppl. 2):S907. 1641P. doi: 10.1016/j.annonc.2023.09.2590